Science-Based Thinking Promises Global Progress On Biosimilars
Samsung Bioepis’ Gillian Woollett Discusses Latest Regulatory Developments
A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.
